newsfilter
← Latest News
GlobeNewswire·

NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates

Company has initiated pre-IND discussions with the FDA for its first AIM INJ indicationNEXI-001 Phase I data to be presented at ASCO 2023 in June GAITHERSBURG, Md., May 15, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc.